Key result
Liraglutide cuts MACE ~11% versus control in patients with T2DM.
Why the study?
To evaluate the cardiovascular effects of liraglutide and provide reassurance regarding its safety and effectiveness in patients with type 2 diabetes mellitus.
Does liraglutide reduce major adverse cardiovascular events in adult patients with type 2 diabetes mellitus?
Meta-Analysis (n=50,751)
Does liraglutide reduce major adverse cardiovascular events in adult patients with type 2 diabetes mellitus?
Liraglutide significantly reduces the risk of major adverse cardiovascular events, myocardial infarction, cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes mellitus.
Supports liraglutide for MACE reduction in type 2 diabetes; confirms benefit across pooled randomized trials.
Diabetes mellitus (DM) is a chronic metabolic disorder, with type 2 diabetes (T2DM) significantly impacting the cardiovascular (CV) system. Our comprehensive study on the cardiovascular effects of liraglutide, conducted concurrently with the formulation of diabetes treatment guidelines, aims to provide healthcare providers and patients with reassurance regarding the safety and effectiveness of liraglutide. From the beginning until August 20, 2023, we conducted searches in databases including PubMed, Web of Science, Embase, Cochrane Library, Scopus, and Google Scholar. These searches aimed to identify studies comparing liraglutide to control in terms of symptom resolution among patients with T2DM. For all relevant outcomes, we calculated risk ratios along with their corresponding 95% confidence intervals. Thirteen randomized controlled trials (RCTs) were included in this analysis. The results demonstrated a significant reduction in the risk of major adverse cardiovascular events (MACE), myocardial infarction, CV mortality, and all-cause mortality. No significant difference was found between the liraglutide and control groups for the outcome of stroke. However, sensitivity analysis revealed a significant reduction in the risk of stroke among patients taking liraglutide. Our comprehensive meta-analysis strongly supports the use of liraglutide for managing cardiovascular disease (CVD) due to its established safety and effectiveness. Further RCTs and meta-analyses are needed to more thoroughly evaluate liraglutide's therapeutic potential, with the aim of enhancing the quality of life for those with CVD.
No takes yet. Share an insight, caveat, or question.
Vemulapalli et al. (2023) conducted a meta-analysis in Type 2 diabetes mellitus (n=50,751). Liraglutide vs. Alternative anti-diabetic treatment or placebo was evaluated on Major adverse cardiovascular events (MACE) (RR 0.89, 95% CI 0.84-0.93, p=<0.00001). Liraglutide significantly reduced the risk of major adverse cardiovascular events by 11% compared to control in patients with type 2 diabetes mellitus (RR 0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: